Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ: SMMT )

19.00 +0.33 (+1.77%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 760,564
Open 18.88
Bid (Size) 18.89 (1)
Ask (Size) 19.00 (2)
Prev. Close 18.67
Today's Range 18.33 - 19.08
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Will Summit Therapeutics Be in 5 Years?
Via The Motley Fool
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool

Performance

YTD
+619.70%
+619.70%
1 Month
-0.99%
-0.99%
3 Month
-16.08%
-16.08%
6 Month
+144.53%
+144.53%
1 Year
+630.77%
+630.77%

More News

Read More
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
How Is The Market Feeling About Summit Therapeutics?
Via Benzinga
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Via The Motley Fool
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
3 Monster Stocks in the Making
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Via Investor's Business Daily
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Via The Motley Fool
Why Summit Therapeutics Stock Was a Winner Today
Via The Motley Fool
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Via MarketBeat
Exposures Product Safety
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
3 Stocks That Have Generated 1,000% Returns in Just 2 Years
Via The Motley Fool
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.